Tivic Health Systems, Inc. (NASDAQ: TIVC) is a medical device company focused on the development and commercialization of non-invasive digital therapeutics designed to treat sinus pain, congestion and related nasal symptoms. Leveraging a proprietary microcurrent platform, Tivic’s technology delivers targeted electrical impulses to reduce inflammation and promote sinus drainage. The company serves patients who suffer from chronic and acute sinusitis, allergy-related congestion and other upper respiratory discomforts, positioning its therapies as a drug-free complement or alternative to traditional medications.
The company’s flagship product, ClearUP™ Sinus Pain Relief, is an FDA-cleared, handheld microcurrent device intended for at-home use. ClearUP operates through gentle pulses applied externally over the sinus passages, and it is available both by prescription and over the counter in select channels. Tivic complements its consumer offering with a digital companion app that guides patients through treatment protocols, tracks symptom relief and provides real-time usage analytics to both users and healthcare practitioners.
Originally founded as Spinifex Pharmaceuticals in 2007, the business shifted its emphasis from drug discovery to digital therapeutics and rebranded as Tivic Health Systems in 2019. Headquartered in Minneapolis, Minnesota, Tivic opened for trading on the Nasdaq under the ticker symbol TIVC in late 2020. The company maintains a growing patent portfolio covering its microcurrent technology and related software algorithms, and it actively engages in clinical research collaborations to expand indications and support evidence-based adoption.
Under the leadership of CEO Greg L. Weitz, Tivic Health Systems continues to broaden its commercial footprint through direct-to-consumer channels, strategic partnerships and distribution networks. While the core market remains the United States, the company has begun pursuing regulatory clearances and strategic alliances in Canada and selected international territories, reflecting its ambition to establish a global presence in the digital therapeutics landscape.
AI Generated. May Contain Errors.
